Cancer is recognized as a preeminent factor of the world's mortality. Although various
modalities have been designed to cure this life-threatening ailment, a significant impediment …

The failure of complete remissions to reliably translate into cures in acute myeloid leukemia
(AML) can be explained by the leukemia stem cell (LSC) paradigm, which hypothesizes that …

The identification of new pathways supporting the myelodysplastic syndrome (MDS)
primitive cells growth is required to develop targeted therapies. Within myeloid …

Multiple studies have demonstrated that ALDH1A1 is elevated in hematopoietic stem cells
(HSCs). As a means to better characterize such cells, we previously developed the …

In acute myeloid leukemia (AML), leukemia‐initiating cells exist within the CD34+/CD38−
cell compartment. They are assumed to be more resistant to chemotherapy, enriched in …

Enrichment of leukemic blasts with a stem cell phenotype correlates with poor survival in
acute myeloid leukemia (AML). In this context, measurement of the stem cell marker …

Leukemic stem cells (LSCs), defined by CD34/CD38 expression, are believed to be
essential for leukemia initiation and therapy resistance in acute myeloid leukemia. In …

Considerable evidence suggests that rare leukemia cells with stem cell features, including
self-renewal capacity and drug resistance, are primarily responsible for both disease …

Although most acute myeloid leukemia (AML) patients achieve complete remissions, the
majority still eventually relapse and die of their disease. Rare primitive leukemia cells, so …

Simple Summary We provide a historical perspective on the current concepts of minimal
residual disease (MRD) and how it evolves from minimal residual disease to measurable …